Arbor Biotechnologies to Present at the Bank of America Global Healthcare Conference
May 03, 2022 07:00 ET
|
Arbor Biotechnologies, Inc.
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its...
Arbor Biotechnologies Announces Presentations at 2022 Annual Meeting of the American Society of Gene & Cell Therapy
May 02, 2022 16:32 ET
|
Arbor Biotechnologies, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced upcoming...
Arbor Biotechnologies Appoints Steven J. Favaloro as Chief Financial Officer
February 22, 2022 07:00 ET
|
Arbor Biotechnologies, Inc.
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs
February 08, 2022 07:00 ET
|
Arbor Biotechnologies, Inc.
BEIJING and CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for...
Arbor Biotechnologies to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022 07:00 ET
|
Arbor Biotechnologies, Inc.
CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its...
Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics
November 09, 2021 07:00 ET
|
Arbor Biotechnologies, Inc.
The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D. ...
Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
August 24, 2021 07:00 ET
|
Arbor Biotechnologies, Inc.
CAMBRIDGE, Mass., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Arbor Biotechnologies (Arbor) today announced a new collaboration to enhance efforts in...